Clinical Trials · NCT01270789
LIraglutide and Beta-cell RepAir (LIBRA) Study
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Mount Sinai Hospital, Canada
- Enrollment
- 63
- Start date
- Jan 2011
- Locations
- 1 site, Canada
- Primary endpoint
- Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2)